Last reviewed · How we verify

Sitagliptin (Novartis, USA)

Al-Azhar University · FDA-approved active Small molecule

Sitagliptin (Novartis, USA) is a DPP-4 inhibitor Small molecule drug developed by Al-Azhar University. It is currently FDA-approved for Type 2 diabetes mellitus.

Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the activity of incretin hormones to increase insulin secretion and decrease glucagon in response to meals.

Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the activity of incretin hormones to increase insulin secretion and decrease glucagon in response to meals. Used for Type 2 diabetes mellitus.

At a glance

Generic nameSitagliptin (Novartis, USA)
SponsorAl-Azhar University
Drug classDPP-4 inhibitor
TargetDPP-4 (dipeptidyl peptidase-4)
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

Sitagliptin is a DPP-4 inhibitor that prevents the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By extending the half-life of these incretin hormones, the drug enhances glucose-dependent insulin secretion and suppresses glucagon release, thereby lowering blood glucose levels in patients with type 2 diabetes. This mechanism is glucose-dependent, meaning it primarily works when blood glucose is elevated, reducing hypoglycemia risk.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Sitagliptin (Novartis, USA)

What is Sitagliptin (Novartis, USA)?

Sitagliptin (Novartis, USA) is a DPP-4 inhibitor drug developed by Al-Azhar University, indicated for Type 2 diabetes mellitus.

How does Sitagliptin (Novartis, USA) work?

Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the activity of incretin hormones to increase insulin secretion and decrease glucagon in response to meals.

What is Sitagliptin (Novartis, USA) used for?

Sitagliptin (Novartis, USA) is indicated for Type 2 diabetes mellitus.

Who makes Sitagliptin (Novartis, USA)?

Sitagliptin (Novartis, USA) is developed and marketed by Al-Azhar University (see full Al-Azhar University pipeline at /company/al-azhar-university).

What drug class is Sitagliptin (Novartis, USA) in?

Sitagliptin (Novartis, USA) belongs to the DPP-4 inhibitor class. See all DPP-4 inhibitor drugs at /class/dpp-4-inhibitor.

What development phase is Sitagliptin (Novartis, USA) in?

Sitagliptin (Novartis, USA) is FDA-approved (marketed).

What are the side effects of Sitagliptin (Novartis, USA)?

Common side effects of Sitagliptin (Novartis, USA) include Nasopharyngitis, Headache, Upper respiratory tract infection, Hypoglycemia (when combined with other agents), Pancreatitis.

What does Sitagliptin (Novartis, USA) target?

Sitagliptin (Novartis, USA) targets DPP-4 (dipeptidyl peptidase-4) and is a DPP-4 inhibitor.

Related